XPHvsBBPETF Comparison
VS
State Street SPDR S&P Pharmaceuticals ETF (XPH) belongs to the US Health Care segment. Virtus LifeSci Biotech Products ETF (BBP) is part of the Tomorrow's Treatments segment. Both ETFs have the same top 1 sector exposures: Healthcare. XPH is more expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.34% for BBP. XPH is up 14.29% year-to-date (YTD) with +$186M in YTD flows. BBP performs better with 31.49% YTD performance, and +$66M in YTD flows. Run a side-by-side ETF comparison of XPH and BBP below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XPH vs BBP performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/27/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XPH BBP | -4.31%-0.29% | -6.56%+8.18% | +14.29%+31.49% | +30.94%+41.36% | +86.70%+131.02% | +44.35%+106.65% |
| Flows | XPH BBP | -$80M- | +$11M+$26M | +$186M+$66M | +$206M+$78M | +$160M+$83M | +$157M+$76M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XPH BBP | +22.82%+28.47% | +23.36%+26.49% | +20.82%+24.96% | +21.10%+26.88% |
| Max drawdown | XPH BBP | -16.58%-8.70% | -16.58%-9.59% | -23.45%-25.54% | -30.87%-37.61% |
| Max drawdown duration | XPH BBP | 69d69d | 69d48d | 322d292d | 1452d586d |
Trading data
XPH | BBP | |
Last sale 10/28/2026 at 1:30 PM | $64.55 | $106.22 |
| Previous close 10/27/2026 | $63.96 | $104.89 |
| Consolidated volume 10/27/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XPH | BBP | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/28/2026 at 1:30 PM
Live
Closed
XPH | BBP | |
|---|---|---|
| Last price | $64.55 | $106.22 |
| 1D performance | +0.92% | +1.27% |
| AuM | $447.54 M | $131.09 M |
| E/R | 0.35% | 0.34% |
Characteristics
XPH | BBP | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | VIRTUS Investment Partners |
| Benchmark | S&P Pharmaceuticals Select Industry Index | LifeSci Biotechnology Products Index |
| N° of holdings | 62 | 66 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 19, 2006 | December 16, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
XPH
USA
89.77%
Other
10.23%
BBP
USA
85.98%
Other
14.02%
Sectors
XPH
Healthcare
93.27%
Other
6.73%
BBP
Healthcare
98.44%
Other
1.56%
Advertisement
Diversification
XPH
Total weight of top 15 holdings out of 15
34.13%
BBP
Total weight of top 15 holdings out of 15
31.08%
Top 15 holdings
Data as of August 31, 2026
XPH
Amylyx Pharmaceuticals, Inc.
3.65%
Crinetics Pharmaceuticals, Inc.
3.60%
MBX Biosciences, Inc.
2.89%
Omeros Corp.
2.68%
Enliven Therapeutics, Inc.
2.28%
Nuvation Bio, Inc.
2.12%
Corcept Therapeutics, Inc.
2.11%
Eton Pharmaceuticals, Inc.
2.08%
Perrigo Co. Plc
1.91%
Edgewise Therapeutics, Inc.
1.85%
Nektar Therapeutics
1.83%
Merck & Co., Inc.
1.81%
Trevi Therapeutics, Inc.
1.80%
Tarsus Pharmaceuticals, Inc.
1.76%
Bristol Myers Squibb Co.
1.75%
BBP
Moderna, Inc.
3.58%
Crinetics Pharmaceuticals, Inc.
2.94%
Omeros Corp.
2.49%
Iovance Biotherapeutics, Inc.
2.36%
Verastem, Inc.
2.15%
Precigen, Inc.
1.99%
Halozyme Therapeutics, Inc.
1.84%
Zai Lab Ltd.
1.82%
Kiniksa Pharmaceuticals International Plc
1.81%
Kura Oncology, Inc.
1.72%
BeOne Medicines Ltd.
1.70%
Rigel Pharmaceuticals, Inc.
1.69%
Nuvation Bio, Inc.
1.69%
ACADIA Pharmaceuticals, Inc.
1.67%
Protagonist Therapeutics, Inc.
1.65%
Frequently asked questions about XPH and BBP
How have the XPH and BBP ETFs performed in 2026?
As of October 27, 2026, XPH is up 14.29% year-to-date (YTD), while BBP has returned 31.49%. That puts BBP better performer ahead so far this year.
Which ETF is attracting more investor money: XPH or BBP?
Year-to-date, the XPH ETF saw +$186M in flows, compared to +$66M for BBP.
Which ETF is more volatile: XPH or BBP?
Over the past year, XPH had a volatility of 23.36%, while BBP experienced 26.49%.
Which ETF is bigger: XPH or BBP?
As of October 27, 2026, XPH holds $447.54 M in assets under management (AUM), while BBP manages $131.09 M.
What sectors do the XPH and BBP ETFs invest in?
XPH leans toward sectors like Healthcare. Meanwhile, BBP focuses on Healthcare.
What are the top holdings of the XPH ETF and BBP ETF?
XPH top holdings include Amylyx Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc. and MBX Biosciences, Inc.. BBP holds in its top three: Moderna, Inc., Crinetics Pharmaceuticals, Inc. and Omeros Corp..
Which ETF is more diversified: XPH or BBP?
XPH holds 62 securities with 34.13% of its assets in the top 15. BBP has 66 securities and a top 15 weight of 31.08%.
Advertisement
Latest news about XPH & BBP
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Advertisement
Advertisement
